Ferric Carboxymaltose-Mediated Attenuation of Doxorubicin-Induced Cardiotoxicity in an Iron Deficiency Rat Model

Table 3

Echocardiographic outcomes according to iron diet, DOX treatment, and supplementation with FCM.

	Group
	1	2	3	4	5	6	7	8
Parameter
LVDD (mm)	8.00±0.09^§	8.01±0.09^§	7.91±0.10^§§	7.90±0.10^§§	8.55±0.11^‡	8.17±0.08^†	7.81±0.10^‖	8.58±0.11
LVSD (mm)	5.01±0.08^∗	5.00±0.09^∗	4.85±0.09^§	4.80±0.10^§	5.80±0.10^∗∗	5.25±0.08^†	4.31±0.11^‖	6.00±0.10
LVPW (mm)	2.36±0.10	2.33±0.12	2.34±0.11	2.33±0.10	2.39±0.12	2.36±0.11	2.30±0.12	2.29±0.10
IVS (mm)	2.36±0.10	2.36±0.11	2.36±0.09	2.36±0.10	2.46±0.11	2.39±0.11	2.31±0.10	2.30±0.10
FS (%)	37.4±0.5^‖‖	37.6±0.5^‖‖	38.7±0.6^§	39.2±0.9^§	32.2±1.0^∗∗	35.7±0.6^†	44.8±1.1^‖	30.1±1.3
LVM (g)	1.33±0.06^¶	1.31±0.07^‡‡	1.28±0.09^‡‡	1.25±0.08^‡‡	1.48±0.06^∗∗	1.36±0.06^††	1.20±0.07^‖	1.32±0.08

Data presented as mean ± SD. A brief tabular overview of treatments in Groups 1–8 is included in Table 2. Further details are described in the Materials and Methods section. LID: low iron diet; ND: normal diet; DOX: doxorubicin; FCM: ferric carboxymaltose; LVDD: left ventricular end-diastolic diameter; LVSD: left ventricular end-systolic diameter; LVPW: left ventricular posterior wall thickness; IVS: interventricular septum thickness; FS: fractional shortening; LVM: left ventricular mass.
^∗𝑃<0.01 versus G3 to G8; ^†𝑃<0.01 versus G7 and G8; ^‡𝑃<0.01 versus G6 and G7; ^§𝑃<0.01 versus G5 to G8; ^‖𝑃<0.01 versus G8; ^¶𝑃<0.01 versus G5 and G7; ^∗∗𝑃<0.01 versus G6 to G8; ^††𝑃<0.01 versus G7; ^‡‡𝑃<0.01 versus G5; ^§§𝑃<0.01 versus G5, G6, and G8; ^‖‖𝑃<0.01 versus G4 to G8.